Latest Regulatory News

Renergen Limited reports significant progress on its merger with ASP Isotopes, resolves a key dispute with Springbok Solar, and reveals promising exploration developments, while managing production and financial challenges.

Australian Pacific Coal Limited has delayed its full year accounts due to missing financial data from its Dartbrook mine subsidiary, leading to a trading suspension from October 1.

Lord Resources has completed a $814,000 placement by issuing 22 million shares, reinforcing its funding position as it advances exploration at the Ilgarari Copper Project in Western Australia.

Tamboran Resources is set to acquire Falcon Oil & Gas Ltd., consolidating a dominant position in the Beetaloo Basin with nearly 3 million net prospective acres. The deal, valued at US$172 million, positions Tamboran as a leading Australian E&P player ahead of key development phases.

Tamboran Resources is set to acquire Falcon Oil & Gas, creating a dominant player with approximately 2.9 million net prospective acres in Australia's Beetaloo Basin. The deal, valued at over US$500 million pro forma, aims to strengthen Tamboran's development footprint and shareholder base.

Australia and New Zealand Banking Group Limited (ANZ) has announced a quarterly distribution of AUD 1.2556 per security on its capital notes, with a 70% franking rate and payment scheduled for December 22, 2025.

OzAurum Resources has launched a targeted drilling campaign at its Mulgabbie North Gold Project, aiming to expand high-grade zones and advance feasibility studies amid record gold prices.

EMU NL’s securities have been suspended from ASX trading due to a failure to maintain the minimum number of directors required by law. The suspension highlights governance challenges and raises questions about the company’s path to compliance.

Paradigm Biopharmaceuticals has dosed participants in its pivotal Phase 3 trial for knee osteoarthritis across the US and Australia, progressing steadily towards a mid-2026 interim analysis.

The Star Entertainment Group has finalized a crucial covenant waiver with its syndicated lenders, easing financial pressures ahead of its FY2025 audited report. This development clarifies ongoing negotiations and sets the stage for the company’s next financial chapter.

Invex Therapeutics Ltd has had its trading suspension lifted following the announcement of a material acquisition, signaling a pivotal moment for the biotech company.

Starpharma has entered a strategic research and option agreement with Radiopharm Theranostics to develop a novel radiotherapy asset using its proprietary dendrimer technology, unlocking potential milestone payments of up to AUD $89 million.